IPSC 2 IMSC:
Legacinetics Exosomes

A primary challenge of MSC’s, and IMSC’s is the limited propensity to complicate via pulmonary obstruction and related agitation at the site of injection. Given MSC’s are generally categorised as cell-based therapies, there is commonly regulatory and mechanical limitations to their broad application, however effective in treating a range of ailment, as has been demonstrated across thousands of studies.
‍

Mesenchymal stem cell (MSC) exosomes are small extracellular vesicles (30–150 nm) secreted by MSCs, including induced MSCs (iMSCs) derived from induced pluripotent stem cells (iPSCs).

These exosomes carry bioactive molecules such as proteins, lipids, mRNAs, microRNAs (miRNAs), and other non-coding RNAs, mediating intercellular communication and exerting therapeutic effects similar to or exceeding those of their parent MSCs.

MSC exosomes, particularly those from iMSCs, are a promising therapeutic platform due to their safety, scalability, stability, and potent paracrine effects. Their benefits—non-cellular nature, low immunogenicity, and customizable cargo—enable applications in regenerative medicine, immunomodulation, neurology, oncology, drug delivery, and diagnostics.

Ongoing clinical trials (e.g., for GvHD, ARDS, and wound healing) and preclinical advancements (e.g., engineered exosomes for cancer) highlight their translational potential. As standardization and regulatory frameworks evolve, MSC exosomes are poised to become a cornerstone of next-generation therapies.